Strong scientific consensus supports the 91.5% market-implied odds against a hantavirus vaccine becoming available in 2026, as all current candidates remain in preclinical or early phase 1 stages with no licensed products yet for New World strains like Andes virus. Recent confirmed outbreaks, including the 2026 cruise ship incident, have prompted renewed preclinical work on DNA, mRNA, and insilicated candidates by teams at institutions such as the University of Bath and collaborations involving Moderna, yet standard regulatory pathways project at least three to four years before initial human trials and five to ten additional years for full approval absent emergency funding comparable to Operation Warp Speed. Trader conviction reflects these extended timelines alongside limited historical investment for sporadic rodent-borne diseases. A sudden surge in cases triggering prioritized federal support or accelerated phase 3 efficacy trials could narrow the gap, though current surveillance data show no such shift.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于Hantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
$93,066 交易量
$93,066 交易量
2026-12-31
$93,066 交易量
$93,066 交易量
2026-12-31
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Strong scientific consensus supports the 91.5% market-implied odds against a hantavirus vaccine becoming available in 2026, as all current candidates remain in preclinical or early phase 1 stages with no licensed products yet for New World strains like Andes virus. Recent confirmed outbreaks, including the 2026 cruise ship incident, have prompted renewed preclinical work on DNA, mRNA, and insilicated candidates by teams at institutions such as the University of Bath and collaborations involving Moderna, yet standard regulatory pathways project at least three to four years before initial human trials and five to ten additional years for full approval absent emergency funding comparable to Operation Warp Speed. Trader conviction reflects these extended timelines alongside limited historical investment for sporadic rodent-borne diseases. A sudden surge in cases triggering prioritized federal support or accelerated phase 3 efficacy trials could narrow the gap, though current surveillance data show no such shift.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
市场开放时间： May 4, 2026, 10:39 AM ET
交易量
$93,066结束日期
2026-12-31市场开放时间
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Strong scientific consensus supports the 91.5% market-implied odds against a hantavirus vaccine becoming available in 2026, as all current candidates remain in preclinical or early phase 1 stages with no licensed products yet for New World strains like Andes virus. Recent confirmed outbreaks, including the 2026 cruise ship incident, have prompted renewed preclinical work on DNA, mRNA, and insilicated candidates by teams at institutions such as the University of Bath and collaborations involving Moderna, yet standard regulatory pathways project at least three to four years before initial human trials and five to ten additional years for full approval absent emergency funding comparable to Operation Warp Speed. Trader conviction reflects these extended timelines alongside limited historical investment for sporadic rodent-borne diseases. A sudden surge in cases triggering prioritized federal support or accelerated phase 3 efficacy trials could narrow the gap, though current surveillance data show no such shift.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
交易量
$93,066结束日期
2026-12-31市场开放时间
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...Strong scientific consensus supports the 91.5% market-implied odds against a hantavirus vaccine becoming available in 2026, as all current candidates remain in preclinical or early phase 1 stages with no licensed products yet for New World strains like Andes virus. Recent confirmed outbreaks, including the 2026 cruise ship incident, have prompted renewed preclinical work on DNA, mRNA, and insilicated candidates by teams at institutions such as the University of Bath and collaborations involving Moderna, yet standard regulatory pathways project at least three to four years before initial human trials and five to ten additional years for full approval absent emergency funding comparable to Operation Warp Speed. Trader conviction reflects these extended timelines alongside limited historical investment for sporadic rodent-borne diseases. A sudden surge in cases triggering prioritized federal support or accelerated phase 3 efficacy trials could narrow the gap, though current surveillance data show no such shift.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题